Mechanisms behind the Resistance to Trastuzumab in HER2-Amplified Breast Cancer and Strategies to Overcome It
The introduction of trastuzumab therapy markedly improved the poor prognosis associated with HER2-amplified breast cancers. Despite this, the presence of primary and acquired resistance to trastuzumab treatment remains a significant common challenge. The identification of resistance mechanisms and t...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2016-01-01
|
| Series: | Clinical Medicine Insights: Oncology |
| Online Access: | https://doi.org/10.4137/CMO.S34537 |
| _version_ | 1818937158535217152 |
|---|---|
| author | Maria Luque-Cabal Paula García-Teijido Yolanda Fernández-Pérez Luisa Sánchez-Lorenzo Isabel Palacio-Vázquez |
| author_facet | Maria Luque-Cabal Paula García-Teijido Yolanda Fernández-Pérez Luisa Sánchez-Lorenzo Isabel Palacio-Vázquez |
| author_sort | Maria Luque-Cabal |
| collection | DOAJ |
| description | The introduction of trastuzumab therapy markedly improved the poor prognosis associated with HER2-amplified breast cancers. Despite this, the presence of primary and acquired resistance to trastuzumab treatment remains a significant common challenge. The identification of resistance mechanisms and the incorporation of new drugs that achieve a better blockade of HER family receptors signaling have resulted in improved outcomes. The phosphatidylinositol 3'-kinase/protein kinase B/mammalian target of rapamycin pathway, cross-talk with estrogen receptors, immune response, cell cycle control mechanisms, and other tyrosine kinase receptors such as insulin-like growth factor I receptor are potential pathways involved in trastuzumab resistance. Different therapeutic interventions targeting these pathways are currently under evaluation. |
| first_indexed | 2024-12-20T05:47:31Z |
| format | Article |
| id | doaj.art-34b133b751bf42bd8c881a3e56dbc8b5 |
| institution | Directory Open Access Journal |
| issn | 1179-5549 |
| language | English |
| last_indexed | 2024-12-20T05:47:31Z |
| publishDate | 2016-01-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Clinical Medicine Insights: Oncology |
| spelling | doaj.art-34b133b751bf42bd8c881a3e56dbc8b52022-12-21T19:51:16ZengSAGE PublishingClinical Medicine Insights: Oncology1179-55492016-01-0110s110.4137/CMO.S34537Mechanisms behind the Resistance to Trastuzumab in HER2-Amplified Breast Cancer and Strategies to Overcome ItMaria Luque-Cabal0Paula García-Teijido1Yolanda Fernández-Pérez2Luisa Sánchez-Lorenzo3Isabel Palacio-Vázquez4Department of Medical Oncology, Hospital Universitario Central de Asturias, Oviedo, Asturias, SpainDepartment of Medical Oncology, Hospital San Agustín, Avilés, Asturias, Spain.Department of Medical Oncology, Hospital Universitario Central de Asturias, Oviedo, Asturias, SpainDepartment of Medical Oncology, Hospital Universitario Central de Asturias, Oviedo, Asturias, SpainDepartment of Medical Oncology, Hospital Universitario Central de Asturias, Oviedo, Asturias, SpainThe introduction of trastuzumab therapy markedly improved the poor prognosis associated with HER2-amplified breast cancers. Despite this, the presence of primary and acquired resistance to trastuzumab treatment remains a significant common challenge. The identification of resistance mechanisms and the incorporation of new drugs that achieve a better blockade of HER family receptors signaling have resulted in improved outcomes. The phosphatidylinositol 3'-kinase/protein kinase B/mammalian target of rapamycin pathway, cross-talk with estrogen receptors, immune response, cell cycle control mechanisms, and other tyrosine kinase receptors such as insulin-like growth factor I receptor are potential pathways involved in trastuzumab resistance. Different therapeutic interventions targeting these pathways are currently under evaluation.https://doi.org/10.4137/CMO.S34537 |
| spellingShingle | Maria Luque-Cabal Paula García-Teijido Yolanda Fernández-Pérez Luisa Sánchez-Lorenzo Isabel Palacio-Vázquez Mechanisms behind the Resistance to Trastuzumab in HER2-Amplified Breast Cancer and Strategies to Overcome It Clinical Medicine Insights: Oncology |
| title | Mechanisms behind the Resistance to Trastuzumab in HER2-Amplified Breast Cancer and Strategies to Overcome It |
| title_full | Mechanisms behind the Resistance to Trastuzumab in HER2-Amplified Breast Cancer and Strategies to Overcome It |
| title_fullStr | Mechanisms behind the Resistance to Trastuzumab in HER2-Amplified Breast Cancer and Strategies to Overcome It |
| title_full_unstemmed | Mechanisms behind the Resistance to Trastuzumab in HER2-Amplified Breast Cancer and Strategies to Overcome It |
| title_short | Mechanisms behind the Resistance to Trastuzumab in HER2-Amplified Breast Cancer and Strategies to Overcome It |
| title_sort | mechanisms behind the resistance to trastuzumab in her2 amplified breast cancer and strategies to overcome it |
| url | https://doi.org/10.4137/CMO.S34537 |
| work_keys_str_mv | AT marialuquecabal mechanismsbehindtheresistancetotrastuzumabinher2amplifiedbreastcancerandstrategiestoovercomeit AT paulagarciateijido mechanismsbehindtheresistancetotrastuzumabinher2amplifiedbreastcancerandstrategiestoovercomeit AT yolandafernandezperez mechanismsbehindtheresistancetotrastuzumabinher2amplifiedbreastcancerandstrategiestoovercomeit AT luisasanchezlorenzo mechanismsbehindtheresistancetotrastuzumabinher2amplifiedbreastcancerandstrategiestoovercomeit AT isabelpalaciovazquez mechanismsbehindtheresistancetotrastuzumabinher2amplifiedbreastcancerandstrategiestoovercomeit |